Last reviewed · How we verify

Inggenol Mebutate 0.015%

Goldman, Butterwick, Fitzpatrick and Groff · FDA-approved active Small molecule

Inggenol Mebutate 0.015% is a Protein kinase C activator Small molecule drug developed by Goldman, Butterwick, Fitzpatrick and Groff. It is currently FDA-approved for Actinic keratosis (field treatment on face or scalp).

Ingenol mebutate activates protein kinase C (PKC) to induce rapid necrosis of actinic keratosis cells and trigger immune-mediated clearance of remaining lesions.

Ingenol mebutate activates protein kinase C (PKC) to induce rapid necrosis of actinic keratosis cells and trigger immune-mediated clearance of remaining lesions. Used for Actinic keratosis (field treatment on face or scalp).

At a glance

Generic nameInggenol Mebutate 0.015%
SponsorGoldman, Butterwick, Fitzpatrick and Groff
Drug classProtein kinase C activator
TargetProtein kinase C (PKC)
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Ingenol mebutate is a diterpene ester that directly activates protein kinase C isoforms in keratinocytes, leading to rapid cell death and disruption of the lesion. Additionally, it stimulates local innate immune responses, including neutrophil infiltration and cytokine production, which contribute to clearance of residual dysplastic cells in the treated area.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Inggenol Mebutate 0.015%

What is Inggenol Mebutate 0.015%?

Inggenol Mebutate 0.015% is a Protein kinase C activator drug developed by Goldman, Butterwick, Fitzpatrick and Groff, indicated for Actinic keratosis (field treatment on face or scalp).

How does Inggenol Mebutate 0.015% work?

Ingenol mebutate activates protein kinase C (PKC) to induce rapid necrosis of actinic keratosis cells and trigger immune-mediated clearance of remaining lesions.

What is Inggenol Mebutate 0.015% used for?

Inggenol Mebutate 0.015% is indicated for Actinic keratosis (field treatment on face or scalp).

Who makes Inggenol Mebutate 0.015%?

Inggenol Mebutate 0.015% is developed and marketed by Goldman, Butterwick, Fitzpatrick and Groff (see full Goldman, Butterwick, Fitzpatrick and Groff pipeline at /company/goldman-butterwick-fitzpatrick-and-groff).

What drug class is Inggenol Mebutate 0.015% in?

Inggenol Mebutate 0.015% belongs to the Protein kinase C activator class. See all Protein kinase C activator drugs at /class/protein-kinase-c-activator.

What development phase is Inggenol Mebutate 0.015% in?

Inggenol Mebutate 0.015% is FDA-approved (marketed).

What are the side effects of Inggenol Mebutate 0.015%?

Common side effects of Inggenol Mebutate 0.015% include Erythema, Flaking/scaling, Crusting, Swelling/edema, Erosion, Pain/burning.

What does Inggenol Mebutate 0.015% target?

Inggenol Mebutate 0.015% targets Protein kinase C (PKC) and is a Protein kinase C activator.

Related